Anthera Pharmaceuticals Inc (ANTH)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

25801 INDUSTRIAL BOULEVARD, SUITE B HAYWARD, CA 94545

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Data as of 2021-07-19 08:50:05 -0400
Market Cap1.458 Million Shares Outstanding26.179 Million Avg 30-day Volume39.24 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE Enterprise Value
Total Cash Current Debt Gross Profit
BETA 52-week High/Low0.189 / 0.01 Next Earnings Date Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ANTH instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ANTH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ANTH BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

MCMANIGLE MARK DREW CHIEF LIQUIDATING OFFICER

0 2018-09-11 0

TRUEX PAUL F

0 2018-01-05 0

HENNEY CHRISTOPHER S

0 2018-01-05 0

THOMPSON DAVID E.

0 2018-01-05 0

LIU MAY PRINCIPAL ACCOUNTING OFFICER

0 2018-01-05 0

SAGER PHILIP

0 2018-01-05 0

MUELLER BRIAN

0 2018-01-05 0

THOMPSON JOHN CRAIG PRESIDENT & CEO

0 2018-01-05 0

FURSE BRENT

0 2018-01-05 0

SHANAHAN WILLIAM R JR CHIEF MEDICAL OFFICER

0 2018-01-05 0

DICKINSON KLARA CHIEF REGULATORY OFFICER

0 2017-05-20 0

OLSON CHARLES V CHIEF TECHNOLOGY OFFICER

0 2017-05-20 0

ENGLE STEVEN B

0 2016-04-27 0

PENNINGTON JAMES INTERIM CHIEF MEDICAL OFFICER

17,688 2016-04-01 0

HISLOP COLIN CHIEF MEDICAL OFFICER

0 2016-02-12 0

ODINK DEBRA CHIEF TECHNOLOGY OFFICER

21,751 2015-10-12 0

ZWEIFACH SANFORD S

0 2015-05-21 0

ZENYAKU KOGYO CO., LTD.

  • 10% Owner
2,795,895 2015-01-27 0

SPIEGELMAN DANIEL K

0 2014-06-13 0

DZIURZYNSKI BOGDAN

10,000 2013-05-31 0

HEALY JAMES

0 2013-05-17 0

LOWE CHRISTOPHER P. CFO AND CHIEF BUSINESS OFFICER

108,915 2013-05-17 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP IV LLC

ISALY SAMUEL D

  • Director
7,462,000 2013-01-30 0

KILFOIL GEORGINA SVP,PRODUCT DEV.& PROJECT MGMT

117,651 2013-01-03 0

THOMPSON PETER A.

  • Director
0 2012-05-08 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA MANAGEMENT VI, L.L.C.

SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

SOFINNOVA VENTURE AFFILIATES VI LP

AZAN ALAIN

POWELL MICHAEL

BUATOIS ERIC

  • 10% Owner
44,969 2011-12-30 0

VANTAGEPOINT VENTURE ASSOCIATES IV LLC

VANTAGEPOINT VENTURE PARTNERS IV Q LP

VANTAGEPOINT VENTURE PARTNERS IV LP

VANTAGEPOINT VENTURE PARTNERS IV PRINCIPALS FUND LP

SALZMAN ALAN E

  • 10% Owner
5,357,528 2011-07-07 0

SANTEL DONALD J

  • Director
0 2011-06-30 0

BIANCHI ANNETTE

  • Director
No longer subject to file 2011-04-19 0

LEHENY A. RACHEL

  • Director
0 2010-09-30 0

TRIAS JOAQUIM SR. VP, PRECLINICAL DEVELOPMEN

  • Officer
198,546 2010-09-21 0

LAU STEPHEN VP, CORP. & BUSINESS DEV.

  • Officer
7,000 2010-06-30 0

FRITSCH URSULA VP, GLOB. REG. & COMPLIANCE

  • Officer
83,615 2010-06-30 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA MANAGEMENT VI, L.L.C.

SOFINNOVA VENTURE PARTNERS VI GMBH & CO. KG

SOFINNOVA VENTURE AFFILIATES VI LP

BUATOIS ERIC

AZAN ALAIN

POWELL MICHAEL

HEALY JAMES

  • Director
  • 10% Owner
45,809 2010-03-04 0

SOFINNOVA VENTURE PARTNERS VI L P

  • 10% Owner
3,983,230 2010-03-04 0

SOFINNOVA MANAGEMENT VI, L.L.C.

  • 10% Owner
4,072,203 2010-03-04 0

SOFINNOVA VENTURE PARTNERS VI L P

SOFINNOVA MANAGEMENT VI, L.L.C.

  • 10% Owner
0 2010-02-23 0

PENNINGTON JAMES E CHIEF MEDICAL OFFICER & EX. VP

  • Officer
105,140 2010-02-23 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 22:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 21:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 21:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 20:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 20:15:05 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 19:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 19:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 18:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 18:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 17:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 17:15:02 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 16:45:02 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 16:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 15:45:02 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 15:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 14:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 14:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 13:45:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 13:15:03 UTC -20.3239 20.4039 850000
ANTHERA PHARMACEUTICALS INC ANTH 2021-07-23 12:45:03 UTC -20.3239 20.4039 850000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments